

Longeveron Inc. (LGVN)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001721484

Longeveron Inc.					
LGVN; healthcare					
Grade	E	 weakest fifth of 371 graded peers percentile 96.8; sampling error 2.5 points; lower is stronger			
Rank	359 of 371				
Profitability	D	 percentile 63.3			
Solvency	E	 percentile 86.6			
Growth and financing	D/E	 percentile 81.8			
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025				
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	under \$12.5M assets total assets \$10.3M				
Standard universe	inside revenue above \$1M and assets above \$10M				
Warnings	short runway not computable: dilution, distress, fortress balance sheet				
Inputs computable	7 of 14				
Graded from	filings received through Mar 17, 2026 206 days before the rescans; latest periodic filing 10-Q received Aug 12, 2026				
Last close	\$2.38 2026-10-08; market equity \$0				
Price used in grade	None				

E, the bear

weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescans that set it

Rescans on file: E from Mar 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across

a spectrum of disease areas.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 63.3						
Gross profitability		7.8%	32.2%	78.7	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(22.7%)	(6.6%)	19.1	811	2025-12-31
Gross margin stability, five years		17.6 pts	2.8 pts	92.1	243	2025-12-31
Solvency, sleeve percentile 86.6						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		(55.12)	(0.31)	89.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31
Interest coverage		not computable	(4.51x)			
Current ratio		1.33x	2.96x	83.5	839	2025-12-31
Growth and financing, sleeve percentile 81.8						
Revenue growth, three-year compound		(0.6%)	10.0%	72.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(27.9%)	2.1%	91.3	704	2025-12-31
Net share issuance, one year		not computable	2.5%			two annual share counts are required; found 0

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 5.9 months



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
354	ALX Oncology Holdings Inc. (ALXO)	95.4	E	dilution, short runway, degenerate inputs, fortress balance sheet
355	Biomerica Inc. (BMRA)	95.7	E	short runway
356	Bolt Biotherapeutics, Inc. (BOLT)	95.9	E	short runway, distress
357	Pfizer Inc. (PFE)	96.2	E	
358	Dare Bioscience, Inc. (DARE)	96.5	E	dilution
359	Longeveron Inc. (LGVN) <	96.8	E	short runway
360	Clene Inc. (CLNN)	97.0	E	dilution, distress
361	Agenus Inc. (AGEN)	97.3	E	dilution, short runway
362	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway
363	Vyome Holdings, Inc. (HIND)	97.8	E	dilution, late filer, fortress balance sheet
364	Sintx Technologies, Inc. (SINT)	98.1	E	dilution, short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	819.9%	8.0%	100
Distance from 52-week high	(71.9%)	(31.4%)	11
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	2.01	(0.14)	100

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail

Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$10.1M
Operating cash flow, four quarters	-\$20.4M
Months of runway	5.9
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$283,317

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$803,000	2025-12-31	2026-03-17	10-K	0001193125-26-110664
2	assets	us-gaap:Assets	\$10.3M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
3	net income	us-gaap:NetIncomeLoss	-\$22.7M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$18.6M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
5	assets	us-gaap:Assets	\$25.6M	2024-12-31	2026-03-17	10-K	0001193125-26-110664
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.2M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
7	gross profit	us-gaap:GrossProfit	\$1.9M	2024-12-31	2026-03-17	10-K	0001193125-26-110664
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.4M	2024-12-31	2026-03-17	10-K	0001193125-26-110664
9	gross profit	us-gaap:GrossProfit	\$221,000	2023-12-31	2025-02-28	10-K	0000950170-25-029968
10	revenue	us-gaap:Revenues	\$709,000	2023-12-31	2024-02-27	10-K	0001213900-24-017521
11	gross profit	us-gaap:GrossProfit	\$497,000	2022-12-31	2024-02-27	10-K	0001213900-24-017521
12	revenue	us-gaap:Revenues	\$1.2M	2022-12-31	2024-02-27	10-K	0001213900-24-017521
13	gross profit	us-gaap:GrossProfit	\$590,000	2021-12-31	2023-03-14	10-K	0001213900-23-020006
14	revenue	us-gaap:Revenues	\$1.3M	2021-12-31	2023-03-14	10-K	0001213900-23-020006
15	current assets	us-gaap:AssetsCurrent	\$5.5M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
16	current liabilities	us-gaap:LiabilitiesCurrent	\$4.1M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$132.3M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
18	operating income	us-gaap:OperatingIncomeLoss	-\$23.3M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
19	book equity	us-gaap:StockholdersEquity	\$5.7M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
20	liabilities	us-gaap:Liabilities	\$4.6M	2025-12-31	2026-03-17	10-K	0001193125-26-110664
21	operating income	us-gaap:OperatingIncomeLoss	-\$18.0M	2022-12-31	2024-02-27	10-K	0001213900-24-017521
22	interest expense	us-gaap:InterestExpense	\$1.4M	2022-12-31	2023-03-14	10-K	0001213900-23-020006
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$245,000	2025-12-31	2026-03-17	10-K	0001193125-26-110664
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$13.9M	2024-12-31	2026-03-17	10-K	0001193125-26-110664
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$655,000	2024-12-31	2026-03-17	10-K	0001193125-26-110664
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$19.0M	2023-12-31	2025-02-28	10-K	0000950170-25-029968
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$301,000	2023-12-31	2025-02-28	10-K	0000950170-25-029968
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$14.0M	2022-12-31	2024-02-27	10-K	0001213900-24-017521
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$569,000	2022-12-31	2024-02-27	10-K	0001213900-24-017521
30	assets	us-gaap:Assets	\$12.1M	2023-12-31	2025-02-28	10-K	0000950170-25-029968
31	assets	us-gaap:Assets	\$27.4M	2022-12-31	2024-02-27	10-K	0001213900-24-017521